Skip to content

Modern glucose-lowering drugs SGLT2 inhibitors and GLP-1 agonists in the prevention of cardiovascular disease and dementia in patients with diabetes and metabolic disorders

Sep 2026 · Terapevt (General Physician) · 0 citations · 10 references

TL;DR

A clinical pharmacological analysis of current data is presented, discussing the mechanisms of action, clinical efficacy, safety, and strategies for personalized use of SGLT2 inhibitors and GLP-1 RAs in preventing cardiovascular and neurodegenerative complications in patients with type 2 diabetes and metabolic disorders.

Abstract

Cardiovascular diseases (CVD) and dementia are two leading causes of mortality and disability in the aging population, and their shared metabolic foundation (insulin resistance, chronic inflammation, and vascular dysfunction) opens new opportunities for pharmacological prevention. Modern glucose-lowering drugs, i.e. sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors, gliflozins) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs), demonstrate pleiotropic effects that extend far beyond glycemic control. Meta-analyses and large cohort studies in recent years confirm their cardio- and renoprotective efficacy, and also point to their potential in reducing the risk of Alzheimer's disease and vascular dementia. The greatest benefit is expected in patients with concomitant cardiovascular and cerebrovascular disease, though definitive confirmation of neuroprotective effects awaits the completion of large randomized trials. This article presents a clinical pharmacological analysis of current data, discussing the mechanisms of action, clinical efficacy, safety, and strategies for personalized use of SGLT2 inhibitors and GLP-1 RAs in preventing cardiovascular and neurodegenerative complications in patients with type 2 diabetes and metabolic disorders.

View source

Similar papers

Review Open access Aug 2026

Type 2 diabetes and the cardio–renal–metabolic syndrome: The evolving roles of GLP-1 and dual GLP-1/GIP receptor agonists

The impact of type 2 diabetes (T2D) extends beyond mere management of blood glucose; it also encompasses related cardiovascular, renal and metabolic issues. This interconnected framework, known as the cardio-renal-metabolic (CRM) syndrome, calls for a shift in therapeutic approach. While traditional treatments have mad...

Clipper F. Young, Namrita George, Alexander Olson et al. · 0 citations
Review Open access Sep 2026

BEYOND GLYCEMIC CONTROL: ORGAN-PROTECTIVE EFFECTS AND SAFETY PROFILE OF GLP-1 RECEPTOR AGONISTS – A COMPREHENSIVE REVIEW

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have evolved from glucose-lowering agents for type 2 diabetes (T2D) into multifunctional therapies with effects extending across multiple metabolic and organ systems. This review summarizes current evidence regarding the pleiotropic effects, safety profile, and futur...

M. Bukowska, Katarzyna Otrębska, Dominika Lewandowska et al. · 0 citations
Review Open access Sep 2026

Cardiovascular protection beyond glucose lowering: GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonism in contemporary cardiology

This Review provides a practical phenotype-directed treatment algorithm incorporating atherosclerotic cardiovascular disease, obesity, type 2 diabetes, chronic kidney disease, HFpEF, sodium–glucose cotransporter 2 inhibitor use and patient-specific treatment constraints.

Ming-Zhen Li · 0 citations
Review Oct 2026

Newer Diabetes Medications in Older Adults with or At Risk for Cardiovascular Disease

SGLT2i and GLP-1 are safe and effective in older patients and offer cardiovascular benefits in older patients with type 2 diabetes with potential benefits of replacing other anti-diabetes agents and reducing polypharmacy.

Laura B. Bovee, Arthi Thirumalai · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.